Sectoral Asset Management Inc. Lowers Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Sectoral Asset Management Inc. lowered its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 89.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 23,872 shares of the company’s stock after selling 198,000 shares during the period. Structure Therapeutics comprises about 1.3% of Sectoral Asset Management Inc.’s investment portfolio, making the stock its 24th largest position. Sectoral Asset Management Inc.’s holdings in Structure Therapeutics were worth $1,660,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. CWM LLC lifted its position in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares during the period. HighTower Advisors LLC lifted its position in Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Structure Therapeutics by 9.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after purchasing an additional 413 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Structure Therapeutics by 4.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $39.19 on Monday. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The business has a 50-day simple moving average of $46.77 and a two-hundred day simple moving average of $56.81. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -45.05 and a beta of -1.31.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.29 earnings per share for the current year.

Analyst Ratings Changes

GPCR has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Finally, Wolfe Research started coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.25.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.